Your session is about to expire
← Back to Search
Psychosocial Intervention for Cognitive Impairment and Depression (PATH-Pain Trial)
N/A
Recruiting
Led By Mannigton C Reid, MD
Research Sponsored by Weill Medical College of Cornell University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Montgomery Asberg Depression Rating Scale (MADRS) total ≥ 5, reflecting at least some mild depressive symptoms
Chronic pain (neuropathic, nociceptive or mixed disorders): presence of pain on most days for at least 3 months and average pain intensity score >=4
Must not have
Requiring psychiatric hospitalization at baseline for safety
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, weeks 5, 9, 24, 36, 52
Awards & highlights
No Placebo-Only Group
Summary
This trial tests PATH-Pain therapy in older adults with cognitive issues, chronic pain, and depression. The therapy aims to help them manage pain, improve mood, and enhance thinking skills through regular sessions.
Who is the study for?
This trial is for older adults over 60 with mild cognitive impairment (MCI) or early-stage Alzheimer's Disease (AD), experiencing chronic pain and some depression. They must have a study partner, be on stable medication if any, and able to consent. Those not fluent in English, at risk of suicide, psychiatrically unstable, or too medically/neurologically unstable are excluded.
What is being tested?
The trial tests Problem Adaptation Therapy for Pain (PATH-Pain) against usual care to see if it improves thinking abilities, mood, and how well people can handle their daily activities when they have memory problems and chronic pain.
What are the potential side effects?
Since PATH-Pain is a psychosocial intervention rather than a drug treatment, side effects may include emotional discomfort during therapy sessions but no physical side effects like those from medication are expected.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I experience mild or more severe symptoms of depression.
Select...
I have had chronic pain most days for at least 3 months with a pain level of 4 or more.
Select...
I have been diagnosed with early Alzheimer's or mild cognitive impairment.
Select...
I am 60 years old or older.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I need to be in a psychiatric hospital for my safety.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline, weeks 5, 9, 24, 36, 52
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, weeks 5, 9, 24, 36, 52
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in cognitive functioning, as measured by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
Secondary study objectives
Change in cognition, as measured by the Alzheimer's Disease Assessment Scale - Cognition Subscale (ADAS-COG)
Change in depressive symptoms, as measured by the Montgomery-Asberg Depression Rating Scale (MADRS)
Change in pain-related disability, as measured by the Roland-Morris Scale
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Problem Adaptation Therapy for Pain (PATH-Pain)Experimental Treatment1 Intervention
Problem Adaptation Therapy-PAIN (PATH-PAIN) is an emotion regulation intervention aimes to reduce stress and decrease depression and disability.
Group II: Attention Control Usual CareActive Control1 Intervention
Usual Care involves the continued medical attention and treatment provided by the subject's physician and other medical professionals in primary care. This may include medical intervention or referrals to specialists to address issues of depression, pain or memory difficulties. Subjects will also be asked to meet with a study research assistant for structured interviews and educational sessions consisting of general questions regarding health habits and other non-medical topics unrelated to cognitive impairment, pain, and depression. Additionally, subjects will receive an educational booklet on pain and depression.
Find a Location
Who is running the clinical trial?
National Institute on Aging (NIA)NIH
1,789 Previous Clinical Trials
28,188,232 Total Patients Enrolled
Weill Medical College of Cornell UniversityLead Sponsor
1,087 Previous Clinical Trials
1,148,647 Total Patients Enrolled
Mannigton C Reid, MDPrincipal InvestigatorWeill Medical College of Cornell University
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I experience mild or more severe symptoms of depression.I have had chronic pain most days for at least 3 months with a pain level of 4 or more.I need to be in a psychiatric hospital for my safety.I am able to understand and agree to the study's requirements.I have been diagnosed with early Alzheimer's or mild cognitive impairment.I am considered medically or neurologically stable enough for research trials.I am 60 years old or older.I haven't taken antidepressants or certain memory drugs, or my dose has been stable for 12 weeks.I have been diagnosed with early Alzheimer's or mild cognitive impairment with a MoCA score between 16 and 25.I have had chronic pain most days for over 3 months with a pain level of 4 or more.You have mild to moderate dementia with a Clinical Dementia Rating score between 0.5 and 1.
Research Study Groups:
This trial has the following groups:- Group 1: Problem Adaptation Therapy for Pain (PATH-Pain)
- Group 2: Attention Control Usual Care
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger